List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9553176/publications.pdf Version: 2024-02-01



LEO KACED

#	Article	IF	CITATIONS
1	Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. Journal of Clinical Oncology, 2003, 21, 2011-2018.	1.6	765
2	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1396-1408.	10.7	356
3	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	2.8	354
4	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. Journal of Clinical Oncology, 2015, 33, 2279-2287.	1.6	329
5	Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncology, 2017, 13, 357-368.	2.4	178
6	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. Journal of Clinical Oncology, 2013, 31, 2303-2312.	1.6	161
7	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117.	8.2	129
8	Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group. Journal of Clinical Oncology, 2006, 24, 1535-1541.	1.6	122
9	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 679-686.	1.5	120
10	NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation. Journal of Clinical Immunology, 2016, 36, 533-540.	3.8	113
11	Advances in the management of osteosarcoma. F1000Research, 2016, 5, 2767.	1.6	105
12	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. Journal of Clinical Oncology, 2016, 34, 3195-3203.	1.6	105
13	Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes and Cancer, 2000, 28, 329-336.	2.8	101
14	Review of mifamurtide in the treatment of patients with osteosarcoma. Therapeutics and Clinical Risk Management, 2010, 6, 279.	2.0	86
15	A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics and Genomics, 2004, 14, 557-567.	5.7	83
16	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83.	8.4	75
17	Cutting Edge: A Hypomorphic Mutation in Igβ (CD79b) in a Patient with Immunodeficiency and a Leaky Defect in B Cell Development. Journal of Immunology, 2007, 179, 2055-2059.	0.8	74
18	Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood, 2020, 136, 2638-2655.	1.4	64

#	Article	IF	CITATIONS
19	Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica, 2007, 92, 1561-1564.	3.5	55
20	Pharmacogenetics in Acute Lymphoblastic Leukemia. Seminars in Hematology, 2009, 46, 39-51.	3.4	55
21	Osteosarcoma in very young children. Cancer, 2010, 116, 5316-5324.	4.1	54
22	Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients. Journal of Clinical Oncology, 2020, 38, 823-833.	1.6	45
23	Polymerase δ deficiency causes syndromic immunodeficiency with replicative stress. Journal of Clinical Investigation, 2019, 129, 4194-4206.	8.2	41
24	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood, 2004, 104, 1435-1441.	1.4	38
25	Pharmacogenomics of acute lymphoblastic leukemia. Current Opinion in Hematology, 2006, 13, 260-265.	2.5	38
26	Highâ€dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival—The Gesellschaft für PÃ d iatrische Onkologie und HÃ # natologie (GPOH) experience. Pediatric Blood and Cancer, 2018, 65, e26746.	1.5	35
27	Direct and Indirect Targets of the E2A-PBX1 Leukemia-Specific Fusion Protein. PLoS ONE, 2014, 9, e87602.	2.5	34
28	Systematic review of the immunological landscape of Wilms tumors. Molecular Therapy - Oncolytics, 2021, 22, 454-467.	4.4	25
29	Thiamine-responsive megaloblastic anemia (TRMA) in an Austrian boy with compound heterozygous SLC19A2 mutations. European Journal of Pediatrics, 2012, 171, 1711-1715.	2.7	24
30	Band 3 null ^{VIENNA} , a novel homozygous <i>SLC4A1</i> p.Ser477X variant causing severe hemolytic anemia, dyserythropoiesis and complete distal renal tubular acidosis. Pediatric Blood and Cancer, 2017, 64, e26227.	1.5	19
31	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. European Journal of Cancer, 2021, 151, 150-158.	2.8	19
32	Denosumab treatment for progressive skull base giant cell tumor of bone in a 14Âyear old female – a case report and literature review. Italian Journal of Pediatrics, 2017, 43, 32.	2.6	16
33	Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin. Cancer Genetics, 2014, 207, 434-436.	0.4	14
34	The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report. Clinical Sarcoma Research, 2016, 6, 3.	2.3	14
35	MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response―randomization Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	14
36	Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia. Haematologica, 2017, 102, e73-e75.	3.5	12

#	Article	IF	CITATIONS
37	Targeted mutation screening of 292 candidate genes in 38 children with inborn haematological cytopenias efficiently identifies novel diseaseâ€causing mutations. British Journal of Haematology, 2018, 182, 251-258.	2.5	12
38	lrinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature—A report from the SIOP Renal Tumor Study Group. Pediatric Blood and Cancer, 2018, 65, e26849.	1.5	11
39	Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy – Case report. Pediatric Hematology and Oncology, 2018, 35, 218-224.	0.8	11
40	Osteosarcoma-Approach to Therapy. Pediatric Oncology, 2021, , 91-109.	0.5	10
41	Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1025-1028.	3.3	9
42	High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients. Sarcoma, 2018, 2018, 1-11.	1.3	9
43	Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093789.	3.2	8
44	Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults. Cancer, 2022, 128, 1787-1800.	4.1	8
45	Clear cell sarcoma of the kidney in Austrian children: Longâ€ŧerm survival after relapse. Pediatric Blood and Cancer, 2021, 68, e28860.	1.5	7
46	Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients. Cancer Management and Research, 2021, Volume 13, 8989-8998.	1.9	7
47	Multiple relapses in highâ€grade osteosarcoma: When to stop aggressive therapy?. Pediatric Blood and Cancer, 2015, 62, 529-530.	1.5	6
48	Two Novel Missense Mutations and a 5bp Deletion in the Erythroid-Specific Promoter of the <i>PKLR</i> Gene in Two Unrelated Patients With Pyruvate Kinase Deficient Transfusion-Dependent Chronic Nonspherocytic Hemolytic Anemia. Pediatric Blood and Cancer, 2016, 63, 914-916.	1.5	6
49	Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK). International Journal of Radiation Oncology Biology Physics, 2020, 108, 667-675.	0.8	6
50	Characteristics of Nephroblastoma/Nephroblastomatosis in Children with a Clinically Reported Underlying Malformation or Cancer Predisposition Syndrome. Cancers, 2021, 13, 5016.	3.7	6
51	Thoracic Actinomycosis With Infiltration of the Spine: An Oncological Pitfall. Journal of Pediatric Hematology/Oncology, 2018, 40, 468-471.	0.6	5
52	Long-term survival of patients suffering from solid extra-cranial neoplasias after dendritic cell-based cancer immune therapy Journal of Clinical Oncology, 2014, 32, 3096-3096.	1.6	5
53	Synchronous and Metachronous Lung Metastases in High-grade Osteosarcoma. Japanese Journal of Clinical Oncology, 2010, 40, 94-95.	1.3	4
54	Novel Compound Heterozygous Mutations in Two Families With Bernard–Soulier Syndrome. Frontiers in Pediatrics, 2020, 8, 589812.	1.9	4

#	Article	IF	CITATIONS
55	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1 Journal of Clinical Oncology, 2015, 33, 10512-10512.	1.6	4
56	MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	4
57	High-dose Methotrexate: The Rationale…. Journal of Pediatric Hematology/Oncology, 2009, 31, 224-225.	0.6	3
58	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma Journal of Clinical Oncology, 2012, 30, 10081-10081.	1.6	3
59	Pharmacogenomics to improve childhood acute lymphoblastic leukaemia therapy. Memo - Magazine of European Medical Oncology, 2009, 2, 65-70.	0.5	2
60	Results of children with renal tumors treated in the Austrian–Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria. Memo - Magazine of European Medical Oncology, 2012, 5, 289-295.	0.5	2
61	Antileukemic drug effects in childhood acute lymphoblastic leukemia. Expert Review of Clinical Pharmacology, 2008, 1, 401-413.	3.1	1
62	Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood. Memo - Magazine of European Medical Oncology, 2018, 11, 54-58.	0.5	1
63	Occurrence of autoimmune pancreatitis after chronic immune thrombocytopenia in a Caucasian adolescent. Clinical Journal of Gastroenterology, 2021, 14, 918-922.	0.8	1
64	Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group Blood, 2005, 106, 1458-1458.	1.4	1
65	Absence of Band 3 in Severe Dyserythropoietic/Hemolytic Anemia with Complete Distal Renal Acidosis and a Novel Homozygous Exon 12 C.1430C>a (p.Ser477X) SLC4A1 Gene Mutation. Blood, 2015, 126, 945-945.	1.4	1
66	Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating del(20q) in a NHEJ1-Deficient Long-term Survivor. Frontiers in Immunology, 0, 13, .	4.8	1
67	Old drug—New insights—Better treatment?. Leukemia Research, 2010, 34, 1558-1559.	0.8	0
68	Pharmacogenomics and Hematologic Diseases. , 2018, , 79-91.		0
69	Extraosseous osteoblastoma: A rare cause of breast mass in a prepubertal girl. Clinical Case Reports (discontinued), 2021, 9, e04094.	0.5	0

70 Osteosarkome. , 2018, , 509-525.

5